Lv51
912 积分 2022-10-10 加入
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
14天前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
14天前
已完结
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
1个月前
已完结
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study
4个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
5个月前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
5个月前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
5个月前
已完结
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
5个月前
已完结
Volume of Distribution in Drug Design
6个月前
已完结
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma
7个月前
已完结
皖公网安备34019202002308
